GlobeNewswire PharmaOriginal article
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
Data ReadoutpositiveCARVYKTIPositive
AI Analysis
Summary
Johnson & Johnson announced five-year follow-up data from CARTITUDE-2 Phase 2 study showing 50% of early line relapsed/refractory multiple myeloma patients treated with single infusion of CARVYKTI achieved treatment-free remission, suggesting potential curative benefit of earlier cilta-cel treatment.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Patients
20
Outcome Details
50% of patients (10/20) in early line relapsed/refractory multiple myeloma remained alive and progression-free for at least five years without maintenance therapy after single infusion
Importance:7/10
Sentiment:
0.90
multiple myelomaCAR-T cell therapylong-term follow-uptreatment-free remissioncilta-cel
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 25, 2026 11:16 AM